MRSA Therapeutics - Pipeline Analysis 2018

Methicillin-resistant Staphylococcus aureus (MRSA) Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments

Published: February 2018
Report Code: LS11401
Available Format:
Pages: 132

Note: This report can also be updated as of date and delivered within 1-2 workings days of purchase confirmation


Methicillin-resistant Staphylococcus aureus (MRSA) is a bacterium that have become resistant to many commonly used antibiotics. While it is a treatable infection, it is a significant public health issue. S. aureus (commonly referred to as "staph") is a common type of bacteria that normally lives on the skin or in the nasal passages of healthy people.





Certain strains of the bacteria that resist the usual antibiotics given to fight staph infections are known as MRSA. Infection can occur when these bacteria enter the body through cut, sore, catheter or breathing tubes. Such infections range from minor such as a pimple, to serious involving the heart, lungs, bloodstream or bones.

The majority of drug candidates has received funding by the various organizations such as Small Business Innovation Research (SBIR) and National Health Service (NHS) that are incentivizing research and development of novel antibiotics for the treatment of MRSA infection. Also, various designations have been awarded to the MRSA drug candidates that speed up the research process involved in the drug development. It has been observed that drug designations such as Qualified Infectious Disease Products designation, Fast track and priority review status, speeding up the process from Phase I to NDA filing are supporting the growth of the MRSA infection therapeutics pipeline.

Pipeline Analysis

As of February 2018, the MRSA therapeutics pipeline comprises of 52 drug candidates in different stages of development.

Competitive Landscape

Some of the key players involved in the development of MRSA therapeutics include GlaxoSmithKline plc, Crystal Genomics Inc., and Innovation Pharmaceuticals Inc.

Place An Order

Single User License

The report will be delivered in PDF format without printing rights. It is recommended for a single user.

USD 2500
Group License

The report will be delivered in PDF format along with the printing rights. It is recommended for up to five users.

USD 3250
Enterprise License

The report will be delivered in PDF format along with printing rights and detailed Excel sheet. It is recommended for organizations where multiple people would like to access the report from multiple locations.

USD 7750

Pre-Purchase Enquiry